The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

The Food and Drug Administration rattled the biotech industry last week when it said it wouldn't even look at Moderna's application to market the first mRNA flu shot. But on Wednesday, the agency ...

The U.S. Food and Drug Administration is refusing to consider a new mRNA flu vaccine made by Moderna, the company revealed in a statement on Tuesday. The vaccine uses mRNA to inoculate the ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday. The move is the latest sign that the FDA, under Health Secretary Robert F.

Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a ...

The Food and Drug Administration reversed course and agreed to begin a review of Moderna’s MRNA3.60%increase; green up pointing triangle application to sell a new seasonal flu shot after the vaccine ...

The Food and Drug Administration rejected Moderna's new flu shot. This raises questions about what it means for the future of vaccine development. Last week, the Food and Drug Administration dealt a ...

WASHINGTON—In an hour-long meeting in January, Food and Drug Administration career staff laid out their objections to a plan to block a new flu shot from vaccine maker Moderna. They argued that ...

Update: The FDA reversed its decision on Feb. 18 and agreed to consider Moderna's application. Read the latest here. Our earlier story is below. The Food and Drug Administration is refusing to ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday. About two weeks ago, the FDA sent Moderna a ...

Moderna Inc.’s shares plunged after U.S. regulators refused to review its novel mRNA flu vaccine, dealing a major blow to the company as it seeks more products beyond its COVID shot. The U.S. Food and ...